EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Comparing the effectiveness and cost-effectiveness of alternative type 2 diabetes monitoring intervals in resource limited settings

Elton Mukonda iD, Maia Lesosky, Siphesihle Sithole, Diederick J van der Westhuizen, Jody A Rusch, Naomi S Levitt, Bronwyn Myers iD, Susan Cleary iD

Health Policy and Planning · 2024

DOI: 10.1093/heapol/czae072 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Health Policy and Planning, 2024. Verfasst von Elton Mukonda und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Epidemiology & Biostatistics, School of Public Health, University of Cape Town, Anzio Road, Cape Town 7925, South Africa. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Cost-Benefit Analysis, Glycated Hemoglobin, Quality-Adjusted Life Years. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, UK Economic and Social Research Council, Wellcome Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Type 2 diabetes (T2D) represents a growing disease burden in South Africa. While glycated haemoglobin (HbA1c) testing is the gold standard for long-term blood glucose management, recommendations for HbA1c monitoring frequency are based on expert opinion. This study investigates the effectiveness and cost-effectiveness of alternative HbA1c monitoring intervals in the management of T2D. A Markov model with three health states (HbA1c <7%, HbA1c ≥ 7%, Dead) was used to estimate lifetime costs and quality-adjusted life years (QALYs) of alternative HbA1c monitoring intervals among patients with T2D, using a provider’s perspective and a 3% discount rate. HbA1c monitoring strategies (three-monthly, four-monthly, six-monthly and annual tests) were evaluated with respect to the incremental cost-effectiveness ratio (ICER) assessing each comparator against a less costly, undominated alternative. The scope of costs included the direct medical costs of managing diabetes. Transition probabilities were obtained from routinely collected public sector HbA1c data, while health service utilization and health-related-quality-of-life (HRQoL) data were obtained from a local cluster randomized controlled trial. Other parameters were obtained from published studies. Robustness of findings was evaluated using one-way and probabilistic sensitivity analyses. A South African indicative cost-effectiveness threshold of USD2665 was adopted. Annual and lifetime costs of managing diabetes increased with HbA1c monitoring, while increased monitoring provides higher QALYs and life years. For the overall cohort, the ICER for six-monthly vs annual monitoring was cost-effective (USD23 22.37 per QALY gained), whereas the ICER of moving from six-monthly to three-monthly monitoring was not cost effective (USD6437.79 per QALY gained). The ICER for four-monthly vs six-monthly monitoring was extended dominated. The sensitivity analysis showed that the ICERs were most sensitive to health service utilization rates. While the factors influencing glycaemic control are multifactorial, six-monthly monitoring is potentially cost-effective while more frequent monitoring could further improve patient HrQoL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Cost-Benefit AnalysisGlycated HemoglobinQuality-Adjusted Life YearsHumansSouth AfricaMarkov ChainsMaleFemaleMiddle AgedQuality of LifeResource-Limited Settings

Stichwörter der Autor:innen

Type-2 diabetescost-effectivenesslow- and middle-income countriesroutine monitoring

Substanzen

Glycated Hemoglobin

Autor:innen und Institutionen

  • Division of Epidemiology & Biostatistics, School of Public Health, University of Cape Town, Anzio Road, Cape Town 7925, South Africa.
  • National Heart and Lung Institute, Imperial College London, 1B Manresa Road, London SW3 6LR, United Kingdom.
  • Division of Chemical Pathology, Department of Pathology, University of Cape Town, Anzio Road, Observatory, Cape Town 7925, South Africa.
  • National Health Laboratory Service, Groote Schuur Hospital, Main Road, Observatory, Cape Town 7935, South Africa.
  • Chronic Disease Initiative for Africa, Department of Medicine, University of Cape Town, Observatory, Cape Town 7925, South Africa.
  • Curtin enAble Institute, Faculty of Health Sciences, Curtin University, GPO Box U1987, Perth WA 6845, Australia.

ORCID-Profile: Elton Mukonda, Bronwyn Myers, Susan Cleary

Förderung

  • Medical Research Council
  • UK Economic and Social Research Council
  • Wellcome Trust
  • National Research Foundation

Zitieren

APA

Mukonda, E., Lesosky, M., Sithole, S., van der Westhuizen, D. J., Rusch, J. A., Levitt, N. S., Myers, B., & Cleary, S. (2024). Comparing the effectiveness and cost-effectiveness of alternative type 2 diabetes monitoring intervals in resource limited settings. Health Policy and Planning. https://doi.org/10.1093/heapol/czae072

Vancouver

Mukonda E, Lesosky M, Sithole S, van der Westhuizen DJ, Rusch JA, Levitt NS, et al. Comparing the effectiveness and cost-effectiveness of alternative type 2 diabetes monitoring intervals in resource limited settings. Health Policy and Planning. 2024. doi:10.1093/heapol/czae072

BibTeX
@article{Mukonda2024,
  author = {Mukonda, Elton and Lesosky, Maia and Sithole, Siphesihle and van der Westhuizen, Diederick J and Rusch, Jody A and Levitt, Naomi S and Myers, Bronwyn and Cleary, Susan},
  title = {Comparing the effectiveness and cost-effectiveness of alternative type 2 diabetes monitoring intervals in resource limited settings},
  journal = {Health Policy and Planning},
  year = {2024},
  doi = {10.1093/heapol/czae072}
}
Kostenlos starten →